These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 27559021)

  • 1. A Bayesian response-adaptive trial in tuberculosis: The endTB trial.
    Cellamare M; Ventz S; Baudin E; Mitnick CD; Trippa L
    Clin Trials; 2017 Feb; 14(1):17-28. PubMed ID: 27559021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian adaptive randomization in a clinical trial to identify new regimens for MDR-TB: the endTB trial.
    Cellamare M; Milstein M; Ventz S; Baudin E; Trippa L; Mitnick CD
    Int J Tuberc Lung Dis; 2016 Dec; 20(12):8-12. PubMed ID: 28240566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The STREAM trial: missed opportunities and lessons for future clinical trials.
    Loveday M; Reuter A; Furin J; Seddon JA; Cox H
    Lancet Infect Dis; 2019 Apr; 19(4):351-353. PubMed ID: 30910428
    [No Abstract]   [Full Text] [Related]  

  • 4. [New antitubercular agents are not where where we need them to be].
    Nau JY
    Rev Med Suisse; 2015 Dec; 11(499):2408-9. PubMed ID: 26852561
    [No Abstract]   [Full Text] [Related]  

  • 5. India plans to expand access to new tuberculosis drug.
    Sharma DC
    Lancet; 2017 Feb; 389(10070):685. PubMed ID: 28229866
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison of multi-arm multi-stage design and adaptive randomization in platform clinical trials.
    Lin J; Bunn V
    Contemp Clin Trials; 2017 Mar; 54():48-59. PubMed ID: 28089763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of incorporating bedaquiline into a treatment regimen for MDR/XDR-TB in Germany.
    Wolfson LJ; Gibbert J; Wirth D; Diel R
    Eur Respir J; 2015 Dec; 46(6):1826-9. PubMed ID: 26493796
    [No Abstract]   [Full Text] [Related]  

  • 8. A Bayesian comparative effectiveness trial in action: developing a platform for multisite study adaptive randomization.
    Brown AR; Gajewski BJ; Aaronson LS; Mudaranthakam DP; Hunt SL; Berry SM; Quintana M; Pasnoor M; Dimachkie MM; Jawdat O; Herbelin L; Barohn RJ
    Trials; 2016 Aug; 17(1):428. PubMed ID: 27577191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A simulation study of outcome adaptive randomization in multi-arm clinical trials.
    Wathen JK; Thall PF
    Clin Trials; 2017 Oct; 14(5):432-440. PubMed ID: 28982263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Barriers to new drug development in respiratory disease.
    Brigden G; du Cros P; Wong S
    Eur Respir J; 2016 Jan; 47(1):356-7. PubMed ID: 26721975
    [No Abstract]   [Full Text] [Related]  

  • 11. A Bayesian sequential design with adaptive randomization for 2-sided hypothesis test.
    Yu Q; Zhu L; Zhu H
    Pharm Stat; 2017 Nov; 16(6):451-465. PubMed ID: 28980435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study.
    Bonnet M; Bastard M; du Cros P; Khamraev A; Kimenye K; Khurkhumal S; Hayrapetyan A; Themba D; Telnov A; Sanchez-Padilla E; Hewison C; Varaine F
    Int J Tuberc Lung Dis; 2016 Feb; 20(2):177-86. PubMed ID: 26792469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-resistance mechanisms and tuberculosis drugs.
    Köser CU; Javid B; Liddell K; Ellington MJ; Feuerriegel S; Niemann S; Brown NM; Burman WJ; Abubakar I; Ismail NA; Moore D; Peacock SJ; Török ME
    Lancet; 2015 Jan; 385(9965):305-7. PubMed ID: 25706840
    [No Abstract]   [Full Text] [Related]  

  • 14. Global Introduction of New Multidrug-Resistant Tuberculosis Drugs-Balancing Regulation with Urgent Patient Needs.
    Sullivan T; Ben Amor Y
    Emerg Infect Dis; 2016 Mar; 22(3):. PubMed ID: 26889711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials.
    Wason JM; Trippa L
    Stat Med; 2014 Jun; 33(13):2206-21. PubMed ID: 24421053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early experience with delamanid-containing regimens in the treatment of complicated multidrug-resistant tuberculosis in Hong Kong.
    Chang KC; Leung EC; Law WS; Leung WM; Tai LB; Lee SN; Lam FM; Chau CH; Mok TY; Yew WW; Leung CC
    Eur Respir J; 2018 Jun; 51(6):. PubMed ID: 29650556
    [No Abstract]   [Full Text] [Related]  

  • 17. A comparison of clinical development pathways to advance tuberculosis regimen development.
    Chang V; Phillips PPJ; Imperial MZ; Nahid P; Savic RM
    BMC Infect Dis; 2022 Dec; 22(1):920. PubMed ID: 36494644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delamanid for multidrug-resistant pulmonary tuberculosis.
    Gler MT; Skripconoka V; Sanchez-Garavito E; Xiao H; Cabrera-Rivero JL; Vargas-Vasquez DE; Gao M; Awad M; Park SK; Shim TS; Suh GY; Danilovits M; Ogata H; Kurve A; Chang J; Suzuki K; Tupasi T; Koh WJ; Seaworth B; Geiter LJ; Wells CD
    N Engl J Med; 2012 Jun; 366(23):2151-60. PubMed ID: 22670901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bayesian dose selection design for a binary outcome using restricted response adaptive randomization.
    Meinzer C; Martin R; Suarez JI
    Trials; 2017 Sep; 18(1):420. PubMed ID: 28886745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simulation study for evaluating the performance of response-adaptive randomization.
    Du Y; Wang X; Jack Lee J
    Contemp Clin Trials; 2015 Jan; 40():15-25. PubMed ID: 25460340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.